scispace - formally typeset
W

Warren M. Zapol

Researcher at Harvard University

Publications -  423
Citations -  26610

Warren M. Zapol is an academic researcher from Harvard University. The author has contributed to research in topics: Nitric oxide & Pulmonary hypertension. The author has an hindex of 81, co-authored 418 publications receiving 25338 citations. Previous affiliations of Warren M. Zapol include Brigham and Women's Hospital & University of British Columbia.

Papers
More filters
Journal ArticleDOI

Pulmonary and Systemic Vascular Resistances After Cardiopulmonary Bypass: Role of Hemolysis

TL;DR: Prolonged CPB was associated with increased plasma hemoglobin and plasma nitric oxide consumption and pulmonary and systemic vascular resistances that after CPB would normalize gradually over time, due to clearance of plasma oxyhemoglobin.
Journal ArticleDOI

Activation of Toll-like receptor 2 impairs hypoxic pulmonary vasoconstriction in mice.

TL;DR: The data indicate that TLR2 activation impairs HPV and induces deleterious systemic effects in mice and suggest thatTLR2 pathways may be important in sepsis-induced respiratory failure.
Book ChapterDOI

Inhaled Nitric Oxide, Clinical Rationale and Applications

TL;DR: Experimental observations initiated a new field of research activity: examining the clinical and experimental effects of inhaled NO in states of pulmonary hypertension of varied etiology with or without concomitant hypoxemia.
Journal ArticleDOI

Platelet function in acute respiratory failure

TL;DR: The results suggest that in vivo platelet activation occurs in ARF, and ARF patients have quantitative and qualitative platelet defects that may contribute to thrombotic and hemorrhagic complications.
Journal ArticleDOI

Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients

TL;DR: Intravenous dipyridamole augments and prolongs the pulmonary vasodilator effects of inhaled NO in CHF patients with severe PH and, when administered in combination with NO inhalation, can identify PH reversibility in potential cardiac transplant recipients in whom a pulmonary vasODilator response to inhalation of NO alone is not observed.